Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy

US10683272B2 · kind B2 · utility

Assignees

• THE JOHNS HOPKINS UNIVERSITY · US
• Northwestern University · US

Inventors

• Sangeeta Ray · Ellicott City, US
• Martin G. Pomper · Baltimore, US
• Thomas J. Meade · Altadena, US
• Ronnie C. Mease · Fairfax, US
• Ying Chen · Timonium, US
• Xing Yang · Baltimore, US
• Matthew Rotz · Carlsbad, US

Key dates

• Filing date: May 6, 2015
• Grant date: Jun 16, 2020
• Expiry date: Mar 18, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K49/108
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.